Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study.

Journal of Diabetes Investigation
Shun KohsakaPeter Fenici

Abstract

There are limited data on cardiovascular efficacy and safety of type 2 diabetes therapies in Japan, where treatments are characterized by lower metformin use and higher dipeptidyl peptidase-4 inhibitor (DPP4i) use versus other countries. We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) matched 1:1 to patients initiating other glucose-lowering drugs (33,890 patients/group) or DPP4i (9,876 patients/group). SGLT2i initiation was associated with lower risks (hazard ratio of in-hospital death [death] 0.56, 95% confidence interval [CI] 0.47-0.67; hospitalization for heart failure 0.75, 95% CI 0.64-0.89; composite of hospitalization for heart failure or death 0.65, 95% CI 0.58-0.74 and stroke 0.66, 95% CI 0.52-0.84 versus other glucose-lowering drugs and lower risks of death 0.52, 95% CI 0.36-0.73) and composite of hospitalization for heart failure or death (0.65, 95% CI 0.51-0.83) versus DPP4i. In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose-lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real-world practice.

References

Jan 28, 2003·Diabetes Care·M WoodwardUNKNOWN Asia Pacific Cohort Studies Collaboration
Feb 26, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Yuji OkuraYoshifusa Aizawa
Dec 25, 2008·Circulation·Hirotsugu UeshimaTomonori Okamura
Jul 7, 2011·Circulation·Anthony S Kim, S Claiborne Johnston
Jul 12, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Jun Hata, Yutaka Kiyohara
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
May 18, 2016·Journal of Diabetes Investigation·Yutaka SeinoDaisuke Yabe
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Mar 16, 2018·Journal of the American College of Cardiology·Mikhail KosiborodUNKNOWN CVD-REAL Investigators and Study Group
Mar 28, 2018·Journal of Diabetes Investigation·Masakazu HanedaEiichi Araki
Aug 23, 2018·Diabetologia·Merlin C Thomas, David Z I Cherney
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.